Background. Abatacept has been suggested to be a safe and effective drug for the treatment of rheumatoid arthritis (RA) complicated by interstitial lung disease (ILD), one of the most severe extra-articular manifestations of RA. Objectives.
Società Italiana di Reumatologia
doaj
Early Outcomes After Haploidentical Hematopoietic Cell Transplantation in Elderly Patients with Myeloid Malignancies in India: A Single Center Experience. [PDF]
Sinha Roy S +8 more
europepmc +1 more source
Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. [PDF]
Sims EK +13 more
europepmc +1 more source
Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a 5-year population-based cohort study. [PDF]
Kao CM, Shih PC, Chen DY, Chen HH.
europepmc +1 more source
Steroid-sparing strategies for managing immune-related adverse events. [PDF]
Huang JJ +4 more
europepmc +1 more source
CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion. [PDF]
Noonan J +22 more
europepmc +1 more source
Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients [PDF]
Akinori Matsumori +30 more
core +1 more source
Developments and Challenges in Treating Rheumatoid Arthritis-Related Interstitial Lung Disease: From Pathogenesis to Treatment Opportunities. [PDF]
Sebastiani M, Luppi F, Bendstrup E.
europepmc +1 more source
Systematic Review of Trial Design and End Points in Lupus Nephritis. [PDF]
Giang S +9 more
europepmc +1 more source

